Tag: glioblastoma

Neoantigens are derived from tumor-specific somatic mutations. As such, they are exempt from immune central tolerance mechanisms and can generate robust immune responses, making them an ideal target for personalized cancer vaccines. Personalized neoantigen vaccination has been previously tested in patients with high-risk melanoma, a cancer that usually harbors...
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial The optimal duration of androgen suppression therapy with radiotherapy for locally advanced prostate cancer is...
1. Compared to maintenance therapy with temozolomide alone, maintenance therapy with Tumor-Treating Fields (TTFields) plus temozolomide significantly improved progression-free and overall survival in glioblastoma patients. 2. The overall adverse event/toxic effect profile of TTFields plus temozolomide combination therapy was comparable to temozolomide treatment alone. Evidence Rating Level: 1 (Excellent) Study Rundown: Glioblastoma...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. A Trial of Treatment for Acute Otorrhea in Children with Tympanostomy Tubes Acute otorrhea is a common post-operative complaint in children who undergo a myringotomy and tubes procedure for restoration...
Image: PD  1. Bevacizumab as a first-line agent alongside temozolomide and radiotherapy increased progression-free survival, but did not increase overall survival.  2. Bevacizumab incorporation was associated with an improved quality of life, but also a higher rate of serious adverse events.  Evidence Rating Level: 1 (Excellent)  Study Rundown: Glioblastoma is a primary brain...
Image: PD  1. When added after initial treatment with temozolomide and radiotherapy, bevacizumab did not improve overall survival in newly diagnosed glioblastoma.  2. Although bevacizumab improved progression-free survival, it was associated with greater deterioration in neurocognitive function and symptom severity. Evidence Rating Level: 1 (Excellent)      Study Rundown: Treatment with bevacizumab, an...